Eventide Asset Management, LLC Sage Therapeutics, Inc. Transaction History

Eventide Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $20.5 Million - $34.1 Million	-790,000 Closed	0 $0
Q3 2019 Nov 21, 2019	BUY	$140.29 - $189.96 $4.91 Million - $6.65 Million	35,000 Added 4.64%	790,000 $111 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $7.89 Million - $9.15 Million	-50,000 Reduced 6.21%	755,000 $138 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $11.7 Million - $21.4 Million	-131,000 Reduced 14.0%	805,000 $128 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $36.2 Million - $61.8 Million	442,000 Added 89.47%	936,000 $89.7 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $17.1 Million - $21 Million	124,000 Added 33.51%	494,000 $69.8 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $16.8 Million - $21.1 Million	120,000 Added 48.0%	370,000 $57.9 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $9.95 Million - $12.6 Million	65,400 Added 35.43%	250,000 $40.3 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $1.55 Million - $4.28 Million	25,600 Added 16.1%	184,600 $30.4 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $9.76 Million - $14.1 Million	159,000	159,000 $9.91 Million

217

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $428M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.